Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael C Jensen

Showing results (1-10 of 134) with videos related to

Pageof 14
Sort By:
Science (New York, N.Y.)|October 31, 2015
IMMUNOLOGY. Synthetic immunobiology boosts the IQ of T cellsMichael C Jensen
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 1, 2008
Engineering GVL through T cell gene transferMichael C Jensen
Cancer Journal (Sudbury, Mass.)|March 27, 2014
CD19CAR T cells: From humble beginnings to cancer immunotherapy's poster childRebecca A Gardner, Michael C Jensen
Current Opinion in Immunology|January 27, 2015
Designing chimeric antigen receptors to effectively and safely target tumorsMichael C Jensen, Stanley R Riddell
Immunological Reviews|December 17, 2013
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cellsMichael C Jensen, Stanley R Riddell
Proceedings of the National Academy of Sciences of the United States of America|April 28, 2010
Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systemsYvonne Y Chen, Michael C Jensen, Christina D Smolke
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2012
Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyondStanley R Riddell, Michael C Jensen, Carl H June
Current Opinion in Immunology|July 24, 2012
Engineered T cells for anti-cancer therapyCameron J Turtle, Michael Hudecek, Michael C Jensen, et al.
Journal of Pediatric Hematology/Oncology|October 9, 2007
Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cellsMichael J Stastny, Christine E Brown, Christopher Ruel, et al.
Current Opinion in Immunology|March 24, 2009
Adoptive transfer of virus-specific and tumor-specific T cell immunityCarolina Berger, Cameron J Turtle, Michael C Jensen, et al.
Pageof 14

Showing results (1-10 of 134) with videos related to

Sort By:
Pageof 14
Science (New York, N.Y.)|October 31, 2015
IMMUNOLOGY. Synthetic immunobiology boosts the IQ of T cellsMichael C Jensen
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 1, 2008
Engineering GVL through T cell gene transferMichael C Jensen
Cancer Journal (Sudbury, Mass.)|March 27, 2014
CD19CAR T cells: From humble beginnings to cancer immunotherapy's poster childRebecca A Gardner, Michael C Jensen
Current Opinion in Immunology|January 27, 2015
Designing chimeric antigen receptors to effectively and safely target tumorsMichael C Jensen, Stanley R Riddell
Immunological Reviews|December 17, 2013
Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cellsMichael C Jensen, Stanley R Riddell
Proceedings of the National Academy of Sciences of the United States of America|April 28, 2010
Genetic control of mammalian T-cell proliferation with synthetic RNA regulatory systemsYvonne Y Chen, Michael C Jensen, Christina D Smolke
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 23, 2012
Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyondStanley R Riddell, Michael C Jensen, Carl H June
Current Opinion in Immunology|July 24, 2012
Engineered T cells for anti-cancer therapyCameron J Turtle, Michael Hudecek, Michael C Jensen, et al.
Journal of Pediatric Hematology/Oncology|October 9, 2007
Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cellsMichael J Stastny, Christine E Brown, Christopher Ruel, et al.
Current Opinion in Immunology|March 24, 2009
Adoptive transfer of virus-specific and tumor-specific T cell immunityCarolina Berger, Cameron J Turtle, Michael C Jensen, et al.
Pageof 14